Envoy Medical Receives Positive Listing Determination from NASDAQ
Envoy Medical (NASDAQ: COCH) received a positive listing determination from the Nasdaq Hearings Panel on October 27, 2025, allowing continued listing while the company addresses compliance with Nasdaq Listing Rule 5550(b)(2).
The Panel cited Envoy Medical's recent equity capital raises and debt extinguishment, which together substantially increased stockholders' equity, and the FDA's approval to advance the fully implanted Acclaim cochlear implant clinical trial to its final stage. The company noted over 28 million shares outstanding and higher trading volume since the trial expansion announcement.
The Panel set a compliance deadline of February 23, 2026; Envoy Medical said it will provide timely updates on progress.
Envoy Medical (NASDAQ: COCH) ha ricevuto una positiva determinazione di quotazione da Nasdaq Hearings Panel il 27 ottobre 2025, che permette la continuazione della quotazione mentre l'azienda risolve la conformità con Nasdaq Listing Rule 5550(b)(2).
Il Panel ha citato i recenti equity capital raises e debt extinguishment di Envoy Medical, che insieme hanno significativamente aumentato il patrimonio netto degli azionisti, nonché l'approvazione da parte della FDA per portare il trial clinico completamente impiantato Acclaim per l'implant cochlear into una fase finale. L'azienda ha indicato oltre 28 million shares outstanding e un volume di scambio più elevato da quando è stato annunciato l'espansione dello studio.
Il Panel ha fissato una scadenza di conformità al February 23, 2026; Envoy Medical ha dichiarato che fornirà aggiornamenti tempestivi sui progressi.
Envoy Medical (NASDAQ: COCH) recibió una determinación positiva de listado por parte del Nasdaq Hearings Panel el 27 de octubre de 2025, que permite la continuación del listado mientras la empresa aborda el cumplimiento de Nasdaq Listing Rule 5550(b)(2).
El Panel citó las recientes equity capital raises y debt extinguishment de Envoy Medical, que en conjunto aumentaron sustancialmente el patrimonio de los accionistas, así como la aprobación de la FDA para avanzar en el ensayo clínico totalmente implantado Acclaim de implante coclear a su etapa final. La empresa señaló más de 28 million shares outstanding y un mayor volumen de operaciones desde el anuncio de la expansión del ensayo.
El Panel fijó una fecha límite de cumplimiento para el February 23, 2026; Envoy Medical afirmó que proporcionará actualizaciones oportunas sobre el progreso.
Envoy Medical (NASDAQ: COCH)가 2025년 10월 27일에 Nasdaq Hearings Panel로부터 긍정적인 상장 결정 를 받아 회사가 Nasdaq Listing Rule 5550(b)(2) 준수를 해결하는 동안 상장을 계속할 수 있게 되었습니다.
패널은 Envoy Medical의 최근 equity capital raises와 debt extinguishment를 언급했고, 이 두 가지가 합쳐 주주 자본을 상당히 증가시켰으며, FDA가 완전히 이식된 Acclaim 인공와우 임상시험을 최종 단계로 진행하도록 승인했다는 점도 지적했습니다. 회사는 유통주식 수가 28 million shares outstanding를 넘어섰고 연구 확장 발표 이후 거래량이 증가했다고 밝혔습니다.
패널은 February 23, 2026까지 준수 마감일을 설정했고, Envoy Medical은 진행 상황에 대해 시기적절한 업데이트를 제공할 것이라고 말했습니다.
Envoy Medical (NASDAQ: COCH) a reçu une détermination positive de cotation du Nasdaq Hearings Panel le 27 octobre 2025, permettant la poursuite de la cotation pendant que l'entreprise s'attelle à se conformer à Nasdaq Listing Rule 5550(b)(2).
Le Panel a cité les equity capital raises et le debt extinguishment récents d'Envoy Medical, qui ensemble ont sensiblement augmenté les capitaux propres des actionnaires, ainsi que l'approbation par la FDA d'avancer l'essai clinique entièrement implanté Acclaim pour l'implant cochléaire jusqu'à sa phase finale. L'entreprise a indiqué plus de 28 million shares outstanding et un volume de négociation plus élevé depuis l'annonce de l'expansion de l'essai.
Le Panel a fixé une date limite de conformité au February 23, 2026; Envoy Medical a déclaré qu'elle fournirait des mises à jour opportunes sur les progrès.
Envoy Medical (NASDAQ: COCH) erhielt am 27. Oktober 2025 eine positive Listing-Entscheidung des Nasdaq Hearings Panel, die eine fortgesetzte Notierung ermöglicht, während das Unternehmen die Einhaltung der Nasdaq Listing Rule 5550(b)(2) sicherstellt.
Das Panel verwies auf Envoy Medials kürzliche equity capital raises und debt extinguishment, die zusammen das Eigenkapital der Aktionäre erheblich erhöhten, sowie auf die FDA-Zustimmung, die vollständig implantierte Acclaim Cochlear-Implantat-Studie in die Endphase zu führen. Das Unternehmen nannte über 28 million shares outstanding und ein höheres Handelsvolumen seit der Ankündigung der Expansions der Studie.
Das Panel setzte eine Compliance-Frist auf den February 23, 2026; Envoy Medical erklärte, dass man zeitnahe Updates zum Fortschritt geben werde.
Envoy Medical (NASDAQ: COCH) تلقت قراراً إيجابياً بشأن الإدراج من فريق جلسات الاستماع في ناسداك في 27 أكتوبر 2025، مما يتيح الإدراج المستمر بينما تعالج الشركة الامتثال لـ Nasdaq Listing Rule 5550(b)(2).
أشار الفريق إلى equity capital raises و debt extinguishment اللذين قامت بهما Envoy Medical مؤخرًا، واللذان معًا رفعا حقوق المساهمين بشكل كبير، بالإضافة إلى موافقة FDA للمضي قدمًا في تجربة زراعة القوقعة Acclaim المزروعة بالكامل إلى مرحلتها النهائية. وأشارت الشركة إلى وجود أكثر من 28 million shares outstanding وأن حجم التداول ارتفع منذ إعلان توسيع التجربة.
حدد الفريق مهلة للامتثال في February 23, 2026؛ وقالت Envoy Medical إنها ستقدم تحديثات في الوقت المناسب عن التقدم.
Envoy Medical (NASDAQ: COCH) 于2025年10月27日从纳斯达克听证小组获得了积极的上市裁定，允许公司在解决对 Nasdaq Listing Rule 5550(b)(2) 的合规问题时继续上市。
小组引用了 Envoy Medical 最近的 equity capital raises 和 debt extinguishment，两者共同显著提升了股东权益，以及FDA批准将完全植入式 Acclaim 耳蜗植入临床试验推进到最终阶段。公司指出流通在外的股票超过 28 million shares outstanding，自试验扩展宣布以来交易量也有所增加。
小组将合规期限定在 February 23, 2026；Envoy Medical 表示将就进展情况及时提供更新。
- Nasdaq Panel granted continued listing through Feb 23, 2026
- Equity raises and debt extinguishment increased stockholders' equity
- FDA cleared advancement to final stage of Acclaim clinical trial
- Shares outstanding exceed 28 million with rising trading volume
- Company remains non-compliant with Nasdaq Rule 5550(b)(2)
- Must demonstrate full compliance by Feb 23, 2026 or risk delisting
White Bear Lake, Minnesota--(Newsfile Corp. - October 27, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that the Nasdaq Hearings Panel (the "Panel) has granted the Company's request for continued listing on the Nasdaq Stock Market.
In granting the extension, the Panel considered several key developments, including Envoy Medical's recent equity capital raises and debt extinguishment, which combined together substantially increased the Company's stockholders' equity, and the FDA's recent approval of the Company's advancement to the final stage of the fully implanted Acclaim® cochlear implant clinical trial. The Company also noted increased investor momentum, with over 28 million shares now outstanding, and a noticeable increase in trading volume since the trial expansion announcement.
The Panel granted Envoy Medical until February 23, 2026, to demonstrate full compliance with Nasdaq Listing Rule 5550(b)(2). This deadline reflects the full extent of the Panel's discretionary authority to allow continued listing while the Company remains non-compliant.
Envoy Medical will continue to provide timely updates to Nasdaq and the public regarding its compliance progress.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain and maintain compliance with Nasdaq rules and requirements; de-listing or removal of Envoy Medical's common stock from Nasdaq; the timing and future outcome of its FDA pivotal trial; the amount of capital required to complete the FDA pivotal trial; the ability to add surgical sites, and the effect of adding such sites; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the number or market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/272006
FAQ
What did Nasdaq decide for Envoy Medical (COCH) on October 27, 2025?
Why did Nasdaq allow Envoy Medical (COCH) to remain listed?
What is Envoy Medical's (COCH) compliance deadline with Nasdaq?
How many Envoy Medical (COCH) shares are outstanding after the financing?
How does the FDA action affect Envoy Medical (COCH)?
